Skip to main
CRBP

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc possesses a promising development pipeline that includes differentiated therapies such as CRB-701, which is noted for its superior safety and efficacy compared to existing antibody-drug conjugates, positioning it well for success in high unmet need areas like head and neck squamous cell carcinoma (HNSCC). Key opinion leaders (KOLs) have expressed optimism regarding CRB-701’s potential for improved survival rates as a second-line therapy, fueled by increased patient access to innovative treatments and a flexible trial design that accommodates a broad patient population. Additionally, encouraging early signals from CRB-913 in weight loss trials further enhance the company's attractiveness in the obesity treatment landscape, suggesting that the diversified portfolio could drive significant growth and market penetration.

Bears say

Corbus Pharmaceuticals Holdings Inc. faces a negative outlook primarily due to potential efficacy and safety concerns surrounding its pipeline candidates, CRB-701 and CRB-913, which could hinder their development and regulatory approval. The company must also navigate competitive pressures from existing and forthcoming therapies, heightening the risk of commercial challenges that may impact future sales estimates. Furthermore, uncertainties related to clinical trial outcomes and regulatory timelines introduce significant risks to the firm’s financial projections and overall market valuation.

CRBP has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 4 analysts, CRBP has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.